Final hours! Save up to 55% OFF InvestingProCLAIM SALE

Biotechs blaze as Trump draft order on drug prices would ease regulations

Published 06/21/2017, 07:22 PM
© Reuters.  Biotechs blaze as Trump draft order on drug prices would ease regulations
LLY
-
MRK
-
VRTX
-
TEVA
-
GILD
-
IBB
-
AMGN
-
BIIB
-
CELG
-
AGN
-
PFE
-
BMY
-
JNJ
-
VTRS
-
BHC
-
NVS
-
PRGO
-
XPH
-
XBI
-
ABBV
-
MNKKQ
-
FBT
-
PPH
-
IHE
-
BBH
-
PBE
-
PJP
-
HQL
-
LABD
-
LABU
-
BBC
-
BBP
-
UBIO
-
ZBIO_OLD
-
  • Biotech stocks (NASDAQ:IBB) were bullish again today, surging another 4.1% and extending this week's sector gain to 8% as sentiment emerges that the Trump Administration's attempt to rein in drug prices might not be as harmful as originally feared.
  • The sentiment got a boost from a NY Times report which cited a draft of an executive order on drug pricing that appears to focus on easing regulatory hurdles for the industry and "largely leaves the drug industry unscathed."
  • The draft "is a far cry from what [Trump] said on the campaign trail. I don't see anything there that addresses the drug companies getting away with murder, and it appears that is because pharma has captured the process," Patients for Affordable Drugs founder David Mitchell told the Times.
  • Among potentially relevant tickers: PFE, MRK, BMY, NVS, LLY, JNJ, AGN, AMGN, BIIB, VRTX, GILD, ABBV, MYL, MNK, TEVA, PRGO, CELG, VRX.
  • ETFs: IBB, XBI, PJP, LABU, BBH, FBT, HQL, XPH, PBE, LABD, IHE, BBC, BBP, PPH, UBIO, ZBIO
  • Now read: Pfizer To Lose Exclusivity Of Key Brands


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.